Stramsen Biotech Submits Pre-IND Package to FDA for SBX1977, Seeks Phase 2 Pathway in Wound Care
Stramsen Biotech Inc., a plant-based biotechnology company, has announced the submission of its Pre-Investigational New Drug (Pre-IND) package to...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Clinical Trials for New Therapy
Stramsen Biotech Inc., a plant-based biotechnology company, has announced the submission of its Pre-Investigational New Drug (Pre-IND) package to...
MONTREAL, Aug. 18, 2025 — Glycovax Pharma has secured a license from the National Research Council of Canada (NRC)...
Shanghai, China, August 26, 2025 – In a landmark advancement, CorrectSequence Therapeutics Co., Ltd. (Correctseq) has announced the first...
Paris, August 14, 2025 – The European Medicines Agency (EMA) has granted orphan drug designation to Sanofi’s rilzabrutinib, a...
Lake Worth, FL. & New York, August 23, 2025 – Thomas H. Lee Partners (THL) has entered into a...
Hong Kong, August 20, 2025 — Akeso, Inc. (9926.HK) has announced the enrollment and dosing of the first patient...
